

## **UBX0101**

**Name:** UBX0101

**Synonyms:** UBX-0101

**Indication:** osteoarthritis

**Company:** UNITY Biotechnology

UBX0101 is designed to treat musculoskeletal disease with an initial focus on osteoarthritis of the knee. UBX0101 is a potent senolytic small molecule inhibitor of the MDM2/p53 protein interaction. Disruption of this protein interaction can trigger the elimination of senescent cells. An Investigational New Drug (IND) application was cleared by the U.S. FDA, and a Phase 1 clinical trial in osteoarthritis of the knee was initiated in the second quarter of 2018. Initial results from the Phase 1 study are expected to be available in the second quarter of 2019.

**A Safety and Tolerability Study of UBX0101 in Patients with Osteoarthritis of the Knee**

**Summary:** This double-blind, randomized, placebo-controlled Phase 1 study is evaluating the safety, tolerability and pharmacokinetics of a single intra-articular injection of UBX0101 into the femoro-tibial joint of patients diagnosed with moderate to severe painful osteoarthritis of the knee.